The Role of Tyrosine Kinase Inhibitor "Lapatinib" in Pulmonary Hypertension

Conclusion Lapatinib might be associated with the development of PAH. PASP should be evaluated in patients who become short of breath while on treatment, and stopping the drug in cases where no other reasons are identified could be associated with reversibility of the elevated pulmonary artery pressure.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research